Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial

被引:16
作者
Letourneau, Joseph [1 ,2 ,3 ]
Juarez-Hernandez, Flor [1 ]
Wald, Kaitlyn [1 ,4 ]
Ribeiro, Salustiano [1 ]
Wang, Ange [1 ]
McCulloch, Charles E. [5 ]
Mok-Lin, Evelyn [1 ]
Dolezal, Milana [6 ]
Chien, A. Jo [7 ]
Cedars, Marcelle I. [1 ]
Rosen, Mitchell [1 ]
机构
[1] Univ Calif San Francisco, Sch Med, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94115 USA
[2] Univ Utah, Sch Med, Dept Obstet & Gynecol, Salt Lake City, UT 84132 USA
[3] Utah Ctr Reprod Med, 675 Arapeen Dr,Suite 205, Salt Lake City, UT 84108 USA
[4] Seattle Reprod Med, Seattle, WA USA
[5] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA
[6] Calif Pacific Med Ctr, Hematol & Oncol, Res Inst, San Francisco, CA USA
[7] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA
关键词
Fertility preservation; Breast cancer; Tamoxifen; Letrozole; Ovarian stimulation; OVARIAN STIMULATION; AROMATASE INHIBITOR; GONADOTROPIN; WOMEN; SUBSEQUENT; CLOMIPHENE; SAFETY;
D O I
10.1007/s10815-021-02273-3
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose To determine whether concomitant tamoxifen 20 mg with gonadotropins (tamoxifen-gonadotropin) versus letrozole 5 mg with gonadotropins (letrozole-gonadotropin) affects mature oocyte yield. Methods Open-label, single-institution, randomized trial. Inclusion criteria included the following: females, ages 18-44 years old, with new diagnosis of non-metastatic breast cancer, who were undergoing fertility preservation with either oocyte or embryo cryopreservation. Those with estrogen-receptor-positive (ER+) breast cancer were randomized to tamoxifen-gonadotropin or letrozole-gonadotropin. Another group with estrogen-receptor-negative (ER-) breast cancer was recruited, as a prospectively collected comparison arm who took neither letrozole nor tamoxifen (gonadotropin only). The primary outcome was the number of mature oocytes obtained from the cycle. The randomized groups were powered to detect a difference of three or more mature oocytes. Results Forty-five patients were randomized to tamoxifen-gonadotropin and fifty-one to letrozole-gonadotropin. Thirty-eight patients completed gonadotropin only. Age, antral follicle count, and body mass index were similar between the randomized groups. Our primary outcome of mature oocyte yield was similar between the tamoxifen-gonadotropin and letrozole-gonadotropin groups (12 +/- 8.6 vs. 11.6 +/- 7.5, p=0.81, 95%CI of difference =-2.9 to 3.7). In a pre-specified secondary comparison, mature oocyte yield was also similar with tamoxifen-gonadotropin or letrozole-gonadotropin versus gonadotropin only (12 +/- 8.6 vs. 11.6 +/- 7.5 vs. 12.4 +/- 7.2). There were no serious adverse events in any of the groups. Conclusions Tamoxifen-gonadotropin and letrozole-gonadotropin produced a similar number of mature oocytes. Women who received either tamoxifen-gonadotropin or letrozole-gonadotropin had a similar number of oocytes to the gonadotropin-only group.
引用
收藏
页码:2455 / 2463
页数:9
相关论文
共 23 条
[1]  
Balkenende, 2019, AM SOC REPROD MED AN
[2]   Effective method for emergency fertility preservation: random-start controlled ovarian stimulation [J].
Cakmak, Hakan ;
Katz, Audra ;
Cedars, Marcelle I. ;
Rosen, Mitchell P. .
FERTILITY AND STERILITY, 2013, 100 (06) :1673-1680
[3]   Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility [J].
Diamond, M. P. ;
Legro, R. S. ;
Coutifaris, C. ;
Alvero, R. ;
Robinson, R. D. ;
Casson, P. ;
Christman, G. M. ;
Ager, J. ;
Huang, H. ;
Hansen, K. R. ;
Baker, V. ;
Usadi, R. ;
Seungdamrong, A. ;
Bates, G. W. ;
Rosen, R. M. ;
Haisenleder, D. ;
Krawetz, S. A. ;
Barnhart, K. ;
Trussell, J. C. ;
Ohl, D. ;
Jin, Y. ;
Santoro, N. ;
Eisenberg, E. ;
Zhang, H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (13) :1230-1240
[4]   Does daily co-administration of letrozole and gonadotropins during ovarian stimulation improve IVF outcome? [J].
Haas, Jigal ;
Bassil, Rawad ;
Meriano, Jim ;
Samara, Nivin ;
Barzilay, Eran ;
Gonen, Noa ;
Casper, Robert F. .
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2017, 15
[5]   Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer [J].
Kim, Jayeon ;
Turan, Volkan ;
Oktay, Kutluk .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (04) :1364-1371
[6]   The effects of letrozole on women with endometriosis undergoing ovarian stimulation for in vitro fertilization [J].
Kim, Se Jeong ;
Choo, Chang Woo ;
Kim, Seul Ki ;
Lee, Jung Ryeol ;
Jee, Byung Chul ;
Suh, Chang Suk ;
Lee, Won Don ;
Kim, Seok Hyun .
GYNECOLOGICAL ENDOCRINOLOGY, 2020, 36 (03) :257-260
[7]   Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome [J].
Legro, Richard S. ;
Brzyski, Robert G. ;
Diamond, Michael P. ;
Coutifaris, Christos ;
Schlaff, William D. ;
Casson, Peter ;
Christman, Gregory M. ;
Huang, Hao ;
Yan, Qingshang ;
Alvero, Ruben ;
Haisenleder, Daniel J. ;
Barnhart, Kurt T. ;
Bates, G. Wright ;
Usadi, Rebecca ;
Lucidi, Scott ;
Baker, Valerie ;
Trussell, J. C. ;
Krawetz, Stephen A. ;
Snyder, Peter ;
Ohl, Dana ;
Santoro, Nanette ;
Eisenberg, Esther ;
Zhang, Heping .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (02) :119-129
[8]   Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation [J].
Letourneau, Joseph M. ;
Wald, Kaitlyn ;
Sinha, Nikita ;
Juarez-Hernandez, Flor ;
Harris, Eve ;
Cedars, Marcelle, I ;
McCulloch, Charles E. ;
Dolezal, Milana ;
Chien, A. Jo ;
Rosen, Mitchell P. .
CANCER, 2020, 126 (03) :487-495
[9]   Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies [J].
Meirow, Dror ;
Raanani, Hila ;
Maman, Ettie ;
Paluch-Shimon, Shani ;
Shapira, Moran ;
Cohen, Yoram ;
Kuchuk, Irena ;
Hourvitz, Ariel ;
Levron, Jacob ;
Mozer-Mendel, Michal ;
Brengauz, Masha ;
Biderman, Hana ;
Manela, Daphna ;
Catane, Rephael ;
Dor, Jehoshua ;
Orvieto, Raoul ;
Kaufman, Bella .
FERTILITY AND STERILITY, 2014, 102 (02) :488-U221
[10]   Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy [J].
Moore, Halle C. F. ;
Unger, Joseph M. ;
Phillips, Kelly-Anne ;
Boyle, Frances ;
Hitre, Erika ;
Porter, David ;
Francis, Prudence A. ;
Goldstein, Lori J. ;
Gomez, Henry L. ;
Vallejos, Carlos S. ;
Partridge, Ann H. ;
Dakhil, Shaker R. ;
Garcia, Agustin A. ;
Gralow, Julie ;
Lombard, Janine M. ;
Forbes, John F. ;
Martino, Silvana ;
Barlow, William E. ;
Fabian, Carol J. ;
Minasian, Lori ;
Meyskens, Frank L., Jr. ;
Gelber, Richard D. ;
Hortobagyi, Gabriel N. ;
Albain, Kathy S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (10) :923-932